[1]祝小惠,梁志文,曹婷,等.SRS MapCHECK半导体矩阵用于射波刀脊柱计划剂量验证的应用研究[J].中国医学物理学杂志,2022,39(4):415-420.[doi:DOI:10.3969/j.issn.1005-202X.2022.04.004]
 ZHU Xiaohui,LIANG Zhiwen,CAO Ting,et al.Application of SRS MapCHECK semiconductor detector array in dose verification for spine CyberKnife plan[J].Chinese Journal of Medical Physics,2022,39(4):415-420.[doi:DOI:10.3969/j.issn.1005-202X.2022.04.004]
点击复制

SRS MapCHECK半导体矩阵用于射波刀脊柱计划剂量验证的应用研究()
分享到:

《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]

卷:
39卷
期数:
2022年第4期
页码:
415-420
栏目:
医学放射物理
出版日期:
2022-04-27

文章信息/Info

Title:
Application of SRS MapCHECK semiconductor detector array in dose verification for spine CyberKnife plan
文章编号:
1005-202X(2022)04-0415-06
作者:
祝小惠1梁志文1曹婷1韩军1王皓宁2龙浩2杨晶1
1.华中科技大学同济医学院附属协和医院肿瘤中心, 湖北 武汉 430022; 2.中南民族大学电子信息工程学院, 湖北 武汉 430074
Author(s):
ZHU Xiaohui1 LIANG Zhiwen1 CAO Ting1 HAN Jun1 WANG Haoning2 LONG Hao2 YANG Jing1
1. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China 2. School of Electronic and Information Engineering, South-Central Minzu University, Wuhan 430074, China
关键词:
SRS MapCHECK半导体矩阵射波刀脊柱临床计划剂量验证γ通过率
Keywords:
Keywords: SRS MapCHECK semiconductor array CyberKnife spine clinical plan dose verification gamma passing rate
分类号:
R318;R811.1
DOI:
DOI:10.3969/j.issn.1005-202X.2022.04.004
文献标志码:
A
摘要:
目的:评估SRS MapCHECK半导体矩阵探测器用于射波刀脊柱计划剂量验证工作的适用性。方法:将SRS MapCHECK探测器安装于专用模体StereoPHAN开展研究工作,测试了射波刀固定和Iris可变准直器的单野计划,以及脊柱临床计划的质量保证(QA)计划,采用SNC Patient软件对比分析实测与计划剂量分布之间的差异,分别计算在2 mm/5%、2 mm/3%和2 mm/2%标准下的γ通过率。结果:在绝对剂量分析模式2 mm/5%,2 mm/3%和2 mm/2%标准下,固定和Iris可变准直器单野计划的γ通过率均为100.0%,脊柱QA计划的平均γ通过率分别为(99.3±1.2)%、(96.5±2.7)%和(93.5±5.3)%。结论:SRS MapCHECK半导体矩阵探测器在2 mm/5%和2 mm/3%的γ分析标准下适合用于开展射波刀脊柱临床计划的剂量验证工作。
Abstract:
Abstract: Objective To evaluate the applicability of SRS MapCHECK semiconductor detector in dose verification for spine CyberKnife plan. Methods SRS MapCHECK detector was installed in the specific StereoPHAN phantom to conduct research. The single-field plans delivered by CyberKnife fixed and Iris variable collimators, as well as the quality assurance (QA) plans for spine clinical plans were tested. SNC Patient software was used to compare and analyze the differences between the measured and planned dose profiles, and the gamma passing rates for the criteria of 2 mm/5%, 2 mm/3% and 2 mm/2% were calculated. Results In absolute dose analysis mode and under the criteria of 2 mm/5%, 2 mm/3% and 2 mm/2%, all the gamma passing rates of the single-field plans delivered by fixed or Iris variable collimators reached 100.0%, and the average gamma passing rates of the spine QA plans were 99.3%±1.2%, 96.5%±2.7% and 93.5%±5.3%, respectively. Conclusion SRS MapCHECK semiconductor detector is suitable for the quick dose verification for spine CyberKnife plans under the gamma criteria of 2 mm/5% and 2 mm/3%.

相似文献/References:

[1]袁玲,刘颖,徐瑶瑶,等.SRS MapCHECK与EDOSE在立体定向放疗计划剂量验证中的对比[J].中国医学物理学杂志,2022,39(1):23.[doi:DOI:10.3969/j.issn.1005-202X.2022.01.004]
 YUAN Ling,LIU Ying,XU Yaoyao,et al.Comparison of dose verification by SRS MapCHECK versus EDOSE for stereotactic radiotherapy[J].Chinese Journal of Medical Physics,2022,39(4):23.[doi:DOI:10.3969/j.issn.1005-202X.2022.01.004]

备注/Memo

备注/Memo:
【收稿日期】2021-11-25 【基金项目】国家自然科学基金(12075322);华中科技大学同济医学院附属协和医院院内科学研究(02.03.2018-131) 【作者简介】祝小惠,硕士,主管技师,研究方向:放射治疗技术,E-mail: zhuxiaohui@hust.edu.cn 【通信作者】杨晶,E-mail: jingy200@hust.edu.cn
更新日期/Last Update: 2022-04-27